Due to current travel restrictions, all individuals requiring a visa to attend the 17th World Congress on IFV are urged to begin making travel arrangements and obtaining necessary visas up to six months prior to attending the Congress. Information about visa requirements can be found on the World Travel Guide website:www.worldtravelguide.net
ISIVF 2013: 17th World Congress on In Vitro Fertilization
le Palace Hotel *Tunis, TUNISIA Visit the Venue to read more
1. The prospect of Stem Cell research
Honorary President of the congress:
Alan Trounson PhD, FRCOG, FANZCOG:
President California Institute Regenerative Medicine
B.Sc. (Hons), M.Sc. University NSW, Ph.D. Sydney University, Australia; Dr Honoris Causa, Vrije Universiteit Brussels; Hon LLD Monash University
Appointed the Dalgety Postdoctoral Fellow ARC Institute of Biochemistry and Reproductive Biology (1974-6), Cambridge, UK. His research on oocyte and embryo manipulation, embryo freezing and non-surgical methods for embryo transfer in cattle, sheep and other species was commercialized in a $ multi-million industry in cattle embryo transfer and artificial breeding. Joined Professor Carl Wood at Monash University in 1977 to pioneer human in vitro fertilization (IVF) and he and Wood established Monash IVF Pty - 1981(sold for $200 million in 2007 - $100 million to Monash University). Subsequently he founded IVF Australia/IVF America Inc. in the US 1987 (now IntegraMed Inc. - revenue 2009-10 $217mill) and co-founded Sydney IVF Pty Ltd 1988 (revenue 6 months 2009 – $37mill).
In the mid-1990's he led a team to discover human embryonic stem cells and their directed their differentiation into nerve and other tissue cells (published 2000). Appointed Director of the Monash Centre for Early Human Development 1985-2002 and founding Deputy Director/Director of the Institute for Reproductive Biology 1990- 2002. Founded the start-up companies Embryonic Stem Cell International (ESI) Pte (merged with Biotime Inc. 2010 – m.c. $246 million 2011) and Maccine Pte (private pharma service company in Singapore).
Founded the first Australian Biotechnology Centre of Excellence - Australian Stem Cell Centre in 2003 ($110 million) and was the founding CEO. He established the Monash Immunology and Stem Cell Laboratories (MISCL) 2004-2007 with >200 research and support staff, recognized as one of the world's leading stem cell research institutes.
In Jan. 2008-present, he was appointed President of the California Institute for Regenerative Medicine, responsible for the management of the $3 billion fund for stem cell research in California (CIRM) . Under his leadership CIRM has constructed 12 new Californian Stem Cell Research Institutes, raising more than $800 Million in donor contributions. These were opened within 2 years of beginning construction. He has developed training programs for new scientists entering stem cell science, drawing a large number if MD-PhD and PhD researchers into the discipline. He established"Bridges" programs that enable students from State Colleges and Universities to train new stem cell courses and to provide 1-2 year fellowships in the major stem cell centers of Californian University and Biotechnology companies. These students from resource-limited environments have proven to be extraordinary success. He has also created awards for high school students to spend summer vacations training in stem cell centers in addition to another discipline (e.g. imaging, engineering, music, ballet physics etc.). These Creativity awards have proven to be very successful and highly sought after. He has overseen and extraordinary development of basic science which has led to more than 1000 publications (24% in high impact factor journals) in peer reviewed journals in the 4 years of his tenure as President. These studies are revolutionizing development and clinical applications of stem cell science. Has globalized the stem cell research program and led the translation of basic science discovery into translation and clinical trials that includes: potential new treatments of blood cancers and solid tumors (3 Phase I already completed and transferred to pharmaceutical companies), spinal cord injury, a cure of HIV/AIDS (based on mutation of the CCR5 gene or shRNA interference), and treatments for macular degeneration (age related blindness), type I diabetes, ALS – motor neuron disease, stroke, heart disease, genetic diseases and neurodegenerative diseases (see cirm website).
2. Genome sequencing and reproductive health:
Professor of Medical Genetics, Division of Medical Genetics, University of Geneva Medical School, Director, Division of Medical Genetics, University and Cantonal Hospital of Geneva. Geneva Switzerland.
3. The place of surgery in the era of ART in the 21st century:
Jean Bernard Dubuisson
4. The IVF Laboratory in the 21st Century:
Marcos Meseguer (Spain)
Dr. Marcos Meseguer was born in November 1974, received his Biological Sciences Degree in 1997 from the University of Valencia in Spain.
He performed a pre-doctoral fellowship in St Mary´s Hospital, Manchester University, United Kingdom. He received his Ph.D. Degree in Obstetrics and Gynecoloy in 2002 from the University of Valencia, Spain, and the European Doctor Degree form the same university. He has also a master degree in Research Methods; Design and Statistics from Universidad Autónoma de Barcelona, Spain. He was Co-Director of the Andrology Laboratory at the Instituto Valenciano de Infertilidad (IVI) from 2000 to 2004. Actually is Senior Embriologist in the IVF unit of IVI Valencia. Dr. Meseguer is a member of various scientific societies and has received the prize paper of the Society of Reproduction and Infertility (American Society of Reproductive Medicine). Three times the Lalor Foundation International Award from the American Society of Andrology and four times the reasearch award from the Spanish Society of Fertility. He has also received the 2011 annual Robert G. Edwards Prize Paper Award for the best paper published in the journal Reproductive BioMedicine Online.
The primary areas of his research are embryology and male infertility. As Principal Investigator, his work has been funded through 9 projects sponsored by the Spanish Government and the Valencian Government, including two EUREKA projects (granted to high quality technological projects) supported by the European Community. He has published over 95 articles and 40 reviews or book chapters, made more than 270 presentations at national and international congresses. He has been the Director of 5 Doctoral Thesis all qualified with "Cum Laude", and actually is directing 6 doctoral theses. He is currently Statistics Assessor and Scientific Supervisor of Equipo IVI the biggest infertility clinic group in Spain and one of the most important in Europe, and associate professor of the Master in Biotechnology from Valencia University.
5. Does PGD/PGS have a real impact on ART efficiency?
Joyce Harper (U K)
6. Uterine and Ovarian Transplantation : advances and controversies :
Matts Brännström , Sweden
7. Endometrium regeneration: research and clinical practice
Carlos Simon (Spain)
Prof. Carlos Simon is Board Certified and Full Professor of Obstetrics and Gynecology at the University of Valencia,
Scientific Director of the Fundación IVI and Scientific Director of Prince Felipe Research Center (2009 – 2011).
Since 1991, his basic and clinical research has contributed to the advance of Reproductive Medicine, specifically in the understanding of human endometrial receptivity, embryo viability, embryonic implantation and endometriosis. He discovered the relevance of the interleukin-1 system in embryonic implantation (Simon et al., JCEM 1993; 1994; Endocrinology 1994; BOR 2006). He demonstrated the deleterious effect of high hormonal levels in patients with high response to gonadotrophins thus modifying the established clinical practice (HR1995; Fertil Steril 1996;1998). He pioneered the concept that human oocytes are affected in endometriosis ( HR 1994; Fertil Steril 2000) thus changing the clinical practice in oocyte donation. He proposed a new embryo coculture system, now successfully used worldwide (JCEM 1996;Fertil Steril 2003). His basic research on endometrial receptivity led him to create and patent a customized array named endometrial receptivity array (ERA) for the molecular diagnosis of endometrial receptivity (Fertil Steril 2010). In an independent bibliometric analysis considering publications in Reproductive Biology between 2003 and 2005, Carlos Simon was identified as the 9th most productive author in the world (Gonzalez-Alcaide G et al., Fertil Steril 90:941-56,2008).
Since 2001, he has expanded his research into the field of stem cells, resulting in the derivation, characterization, and registration in the Spanish National Stem Cell Bank (BNLC) of ten human embryonic stem cell (hESC) lines (http://www.isciii.es/ISCIII/es/contenidos/fdinvestigacion/ fd-ejecucion/fd-programas-investigacion/fd-investigacionterapiacelular- medicina-regenerativa/banco-nacional-lineas-celulares.shtml). He derived the first two hESC in Spain (Fertil Steril 2005) and described a new system for freezing hESC in the absence of animal contaminants. He derived VAL-6M, the first line with a monogenic disorder (Myotonic Dystrophy Type I) in Spain. Also, he obtained the first two hESC lines without destroying the human embryo using blastomere biopsy and demonstrated the lack of genetic diversity in the most common used hESC in the world (Mosher JT et al. N Engl J Med 2010). Finally, he reported the identification and characterization of human endometrial stem cells (Cervelló et al., PLoS ONE. 2010;5(6):e10964).
As Principal Investigator, his work has been funded through 10 projects sponsored by the Spanish Government, 5 by the Valencian Government, including a PROMETEO (granted to prestigious scientists) and 14 projects by international organizations, American Universities and private companies.
He has published a total of 313 papers in international peer-review journals, adding up to an accumulated impact factor of 1.276,207. His papers have received a total of 9.183 cites with an average of 29,34 cites/paper. His H-Index is 52 and he is editor of 14 books. He has been Director of 21 Doctoral Thesis all qualified with "Cum Laude", including 4 PhD Awards of Excellence and one European PhD.
As inventor, his research has originated 11 Patent Applications, leading to the creation of 3 Biotech companies (IVIOMICS, Embryomics & Stemlifeline). He has been awarded "Prize Jaime I 2011 in Medical Investigation"
8. Oocyte and embryo vitrification : a new way of working in ART :
Başak Balaban (Turkey)
- Excursion 1: « Carthage & Sidi Bou Saïd » (Half day excursion): 40,00 € / Person*
- Excursion 2: « Bardo Museum » (Half day excursion): 40,00 € / Person*
- Excursion 3: « Kairouan, El Jem & Sousse» (All day excursion): 75,00 € / Person (lunch included)*
TIME ALLOWANCE FOR PRESENTATION
- Plenary Lecture: 30 minutes (25 minutes presentation and 5 minutes discussion)
- Concurrent sessions: 20 minutes (15 minutes presentation and 5 minutes discussion)
- Free Communication: 10 minutes
AT THE TIME OF YOUR PRESENTATION
- Meet with the session Chairpersons in the session room 15 minutes before the beginning of the session.
- Please be certain that the length of your oral presentation does not exceed the allotted time.
- Chairpersons have been instructed to terminate lectures which exceed their allotted time.
EQUIPMENT FOR PRESENTATION
Power Point Presentation.
Session rooms are provided with one Windows laptop computer on which Microsoft PowerPoint is installed (OS: Windows XP; Software: Microsoft PowerPoint 2003/2007/2010) and an LCD projector. The podium is equipped with a monitor, a mouse and a keyboard. You are requested to bring the data for your presentation on a CD-ROM or a USB memory stick, or your own laptop computer.
- If you bring data:
You are requested to bring the data for your presentation on a CD-ROM or a USB memory stick to the Speaker Ready Room and upload your presentation at least 30 minutes before your session begins. Only a CD-ROM in Windows format or USB memory stick is acceptable. The name of the file should be labeled with your name.
- If you bring your own laptop computer:
Windows machines with Windows 98/98SE/2000/ME/XP/VISTA/7 or Macintosh machines with any Mac OS (8.6/9.04-9.2.2/X.1-X.6 and subsequent versions) are acceptable. Please note that Tunisia operates on 220 volts for electrical appliances, with a cycle of 50 Hz
You are requested to bring your computer and check its connection at the Speaker Ready Room at least 30 minutes before your session begins.
For all computers, check the following settings:
- Cancellation of power-saving features: Cancellation of Sleep, Screen Saver, etc.;
- Resolution of screen: 1024x768 pixels (XGA) or less.
In the session room, please have your computer powered on when the presentation prior to your own begins and hand it over to the operator at the PC desk in the session room, with your presentation file opened. (You may be required to restart your computer if the connection to the projector is not successful.) Since there will be only one connection cable to the projector, the operator will connect it at the beginning of your presentation. The projector has a standard mini-D-sub 15 pin (three sequences) connector. If your computer has a different connector, you should bring your own conversion cable.
- When you make a PowerPoint file for your presentation, please make sure that all graphics are embedded in the presentation file. Fonts should be standard fonts, such as Times New Roman, Arial, or Courier. If non-standard fonts must be used, they should be embedded in the presentation files. Also, please set up the slide size for “On-screen show”.
- If your presentation includes video/animation, only ones that can be played by “Media Player” are acceptable.
- The name of the file should be labeled with your name.
SPEAKER READY ROOM (for slide preview and data check)
Please make sure to visit the room with your data/PC at least 30 minutes before your session begins.
All session chairpersons are requested to meet with their speakers in the session room 15 minutes before the session begins.
- Please welcome delegates to the session and introduce each speaker by title, name of all authors, and affiliation (if any) as listed.
- Any changes to the program should be announced at the beginning of the session.
- An attendant will be present in the session room to assist you with any last minute details.
- Please keep each presentation on schedule. If a presentation is cancelled, do not change the timing of the other presentations.
To provide ample time for all participants to view and discuss poster presentations, each poster will be on display for the entire duration of the Congress.
Poster presenters are requested to be at their posters during the Poster Viewing Time
Poster presenters are responsible for setting up and removing their posters according to the following schedule:
- Setting up: Wednesday, September, 4, 2013 16:00-20:00 or Thursday, September, 5, 2013, 8:00-9:00
- Removal: Saturday, September, 7, 2013, 12:00-15:00
Notes for Poster Presentation:
- All posters are to be written entirely in English.
- A presentation number to be placed at the top left of the poster will be provided by the Secretariat. Each author is requested to indicate the “title”, the “authors’ names” and the “authors’ affiliations”, at the top right of the panel within an area measuring 90cm wide by 20cm high.
- The usable area for the contents is a space 90cm wide and 160cm high. The layout of the presentation contents is at the authors’ discretion.
- Posters are to be attached to the boards with drawing pins, which will be provided at the Poster Area. No paste, glue, staples or nails are permitted.
- Please stay in front of your poster during the Poster Viewing times.
- The best oral and poster award will be presented in the Closing Ceremony on Saturday, September, 7, 2013
Best Abstract Awards
Six abstract awards winners, three for poster and three for oral presentation, will be selected and provided by the International Society for In Vitro Fertilization. The Winners will be announced in the Closing Ceremony.
- Abstracts submitted must contain original work that has not been published or submitted for presentation at any national or international meeting prior to the 17th World Congress on IVF.
- Abstracts must be submitted in English.
- Abstracts will be considered for oral presentation, unless authors specify "Poster Only" on the submission form. Abstracts not selected for oral presentation will be considered for poster presentation.
- Notifications regarding acceptance/rejection will be emailed to the authors from July, 15, 2013.
- Authors presenting abstracts must be registered participants. Presenters that fail to complete their registration by July, 31, 2013 will not be included in the Congress Final Program and Book of Abstracts.
- There will be a limit of two abstracts per presenter.
- All decisions by the Scientific Committee are final. Dates and times of presentations cannot be changed.
- Only abstracts submitted via the website will be accepted; abstracts submitted by fax, post or email will be ignored.
Please note that authors will receive an email confirmation once the submission process is completed. If you do not receive confirmation, your submission may not have been received and you are advised to contact the organizer.
Upon submission of your abstract, you will be issued an "Abstract Submission Number", which is required to view, edit, or delete your submitted abstract. This number is different from the "Registration Number" for conference participation.
The online form requires authors to select one category from the Abstract Categories List. If selected for presentation, the abstract will be presented in a session within the indicated category.
- Male reproduction and urology
- Clinical female infertility and gynecology
- ART - Basic research Indications, Prognostic factors
- ART - Ovarian stimulation
- ART – laboratory procedures
- ART – Implantation
- ART- Cryopreservation
- ART - Infection diseases
- ART - Safety and complications
- ART – Cancer
- ART - Children follow-up
- ART - Imaging techniques
- ART - Reproductive aging and infertility
- ART - Reproductive surgery
- ART - Ethics, law and global perspective
- Early pregnancy
- Fertility Preservation
- Pre-implantation genetic diagnosis
- Psychology & Counseling
- Quality control & management
Abstract Content & Format
- Abstracts must describe the research performed. Only abstracts with the following headings can be considered. Failure to follow this format will disqualify the abstract.
|Introduction Material & Methods||(should be informative and short, stating why the study was conducted)
(indicating the locale, number and type of human subjects, non-human species
or material being studied, the principal procedures, assays, test or treatments performed)
|Results||(confirming or refuting the hypothesis, supported by statistics if appropriate);|
|Conclusions||(stating the major new findings of the study and specifying what these findings
add to what is known already).
- The use of graphs, tables and images is strongly discouraged.
- Do not identify individuals in the title or abstract body.
- Invited speakers are required to submit your brief biography and portrait photo on the abstract submission system.
- Please note that there is limit on the number of institutions, co-authors, abstract title, abstract body and brief biography as follows:
Institution: up to 6
Co-authors: up to 6
Abstract title: up to 200 characters
Abstract body (for Oral/Poster presentation): up to 3,500 characters
Oral & Poster Presentation
Abstracts will be considered for oral presentation, unless authors specify "Poster Only" on the submission form. Abstracts not selected for oral presentation will be considered for poster presentation.
a. Oral presentations will be 10 minutes in length followed by 5 minutes of discussion. Only PowerPoint will be supported.
b. Surface areas of the poster boards are 180 cm high x 90 cm wide.
c. Three of Oral presentation and Three of Poster presentation will be selected for awards.
Secretariat: for inquires regarding individual or group registrations, abstracts, scientific program, accommodation, exhibit and other matters related to the organization of the meeting, please contact: